latest results from the cartitude-2 study testing cilta-cel in multiple myeloma patients
Published 2 years ago • 200 plays • Length 5:34Download video MP4
Download video MP3
Similar videos
-
4:25
updated results from cartitude-1: phase 1b/2study of cilta-cel in pts with rr multiple myeloma
-
3:37
updated data from cartitude-1 and cartitude-2 studies testing cilta-cel in r/r multiple myeloma
-
2:33
latest results from the cartitude-2 trial of cilta-cel in progressive multiple myeloma
-
5:03
cartitude-2: evaluating car t therapy cilta-cel in multiple myeloma patients who had early relapse
-
3:52
updated results (2 years post-lpi) in phase 1b/2 (cartitude-1) study of cilta-cel in rrmm patients
-
1:45
cartitude-2 update: cilta-cel in relapsed and lenalidomide-refractory patients with multiple myeloma
-
2:28
results from the cartitude-2 trial
-
1:21
an update on cartitude-2: cilta-cel in patients with multiple myeloma in second line
-
8:45
updates on clinical data of cilta-cel in cartitude-2 cohort a among progressive mm patients
-
1:26
cilta-cel vs. therapies from real-world clinical practice for triple-class exposed myeloma
-
9:34
neurologic adverse effects in pts with mm treated with cilta-cel in cartitude-2
-
7:25
cilta-cel continues to show promise as a treatment for progressive multiple myeloma
-
5:44
cilta-cel in r/r myeloma: preliminary results from cartitude-1
-
7:41
cartitude-2: ciltacabtagene autoleucel in patients with progressive multiple myeloma
-
4:13
what can newly diagnosed myeloma patients expect in regard to treatment in 2020?
-
2:25
caritude-1: cilta-cel achieves deep and durable responses in r/r myeloma
-
1:10
exciting car-t data in multiple myeloma and follicular lymphoma: cartitude-2, elara & zuma-5
-
7:23
cartitude-2: efficacy and safety of ciltacabtagene autoleucel in patients with progressive mm
-
2:09
cartitude-1: cilta-cel improves hrqol for patients with myeloma